World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update
Antimicrobial resistance is a major public health problem globally. Likewise, forms of
tuberculosis (TB) resistant to first-and second-line TB medicines present a major challenge …
tuberculosis (TB) resistant to first-and second-line TB medicines present a major challenge …
[HTML][HTML] Pretomanid for tuberculosis: a systematic review
T Gils, L Lynen, BC de Jong, A Van Deun… - Clinical Microbiology and …, 2022 - Elsevier
Background Outcomes of treatment of tuberculosis patients with regimens including
pretomanid have not yet been systematically reviewed. Objectives To appraise existing …
pretomanid have not yet been systematically reviewed. Objectives To appraise existing …
A 24-week, all-oral regimen for rifampin-resistant tuberculosis
BT Nyang'wa, C Berry, E Kazounis… - … England Journal of …, 2022 - Mass Medical Soc
Background In patients with rifampin-resistant tuberculosis, all-oral treatment regimens that
are more effective, shorter, and have a more acceptable side-effect profile than current …
are more effective, shorter, and have a more acceptable side-effect profile than current …
[图书][B] WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update
World Health Organization - 2022 - books.google.com
The WHO Consolidated Guidelines on Tuberculosis (TB), Module 4: Treatment-Drug-
Resistant Tuberculosis Treatment 2022 update informs health care professionals in Member …
Resistant Tuberculosis Treatment 2022 update informs health care professionals in Member …
Comparative effectiveness of individualized longer and standardized shorter regimens in the treatment of multidrug resistant tuberculosis in a high burden country
Objective: To compare the effectiveness of second line injectables containing shorter
(duration 9–12 months) and longer treatment regimens (LTR, duration≥ 20 months) among …
(duration 9–12 months) and longer treatment regimens (LTR, duration≥ 20 months) among …
Frequency and factors associated with adverse events among multi-drug resistant tuberculosis patients in Pakistan: A retrospective study
Background Treatment of multi-drug resistant tuberculosis (MDR-TB) for a prolonged period
with comparatively less effective and more toxic second-line anti-TB drugs is associated with …
with comparatively less effective and more toxic second-line anti-TB drugs is associated with …
[图书][B] WHO operational handbook on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment
World Health Organization - 2020 - apps.who.int
The World Health Organization (WHO) has produced this WHO operational handbook on
tuberculosis to provide practical advice to complement the latest WHO consolidated …
tuberculosis to provide practical advice to complement the latest WHO consolidated …
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial
KE Dooley, SL Rosenkranz, F Conradie… - The Lancet Infectious …, 2021 - thelancet.com
Background Bedaquiline and delamanid are the first drugs of new classes registered for
tuberculosis treatment in 40 years. Each can prolong the QTc interval, with maximum effects …
tuberculosis treatment in 40 years. Each can prolong the QTc interval, with maximum effects …
Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in …
Background There is a need for short and safe all-oral treatment of rifampicin-resistant
tuberculosis. We compared outcomes up to 24 months after treatment initiation for patients …
tuberculosis. We compared outcomes up to 24 months after treatment initiation for patients …
Safety of treatment regimens containing bedaquiline and delamanid in the endTB cohort
C Hewison, U Khan, M Bastard… - Clinical Infectious …, 2022 - academic.oup.com
Background Safety of treatment for multidrug-resistant tuberculosis (MDR/RR-TB) can be an
obstacle to treatment completion. Evaluate safety of longer MDR/RR-TB regimens …
obstacle to treatment completion. Evaluate safety of longer MDR/RR-TB regimens …